Cytokeratin 7 (CK7) is a structural protein found in the lining of certain organs, and pathologists use it as one of their most reliable tools for figuring out where a cancer started. When a tumor shows up in an unexpected place, or when a biopsy reveals cancer cells but nobody knows which organ spawned them, staining the tissue for CK7 often narrows the list of suspects dramatically. The protein itself is not unique to cancer; it exists in healthy tissue, too. What makes it diagnostically powerful is its selective distribution: some organs consistently produce it, others consistently do not, and cancer cells tend to carry these same molecular fingerprints even after they have spread far from home.
A Protein With a Very Specific Address Book
CK7 belongs to a large family of proteins called cytokeratins (or just keratins) that form the internal scaffolding of epithelial cells, the cells lining your organs, skin, and glands. There are more than 20 distinct cytokeratins, each with its own tissue preferences. CK7 shows up in the columnar and glandular linings of the lung, breast, and cervix, in bile ducts, in the collecting ducts of the kidney, and in the mesothelium (the thin membrane wrapping your lungs and abdomen). It is also strongly expressed throughout all layers of the bladder’s transitional epithelium. But it is absent from the gastrointestinal lining, from liver cells, from the proximal and distal tubules of the kidney, and from stratified (layered) surfaces like skin, tongue, and esophagus.1Experimental Cell Research. Tissue distribution of keratin 7 as monitored by a monoclonal antibody
This selective pattern is what gives CK7 its diagnostic value. A cancer cell that arose in the lung will usually still make CK7, even if that cell has traveled to the liver. A cancer cell from the colon, which never made CK7 in the first place, will usually remain CK7-negative even after it has spread elsewhere. In a sense, cancer cells carry a molecular passport stamped with their tissue of origin, and CK7 is one of the stamps pathologists check.
The CK7/CK20 Coordinate System
CK7 is rarely used alone. Its real power comes from being paired with another cytokeratin, CK20, which has its own distinct tissue preferences (mostly the gastrointestinal tract, bladder lining, and Merkel cells in the skin). By testing a tumor sample for both proteins, a pathologist gets a two-variable profile that slots the cancer into one of four categories:
- CK7-positive, CK20-negative: Points toward lung, breast, endometrial, thyroid, salivary gland, ovarian serous, or mesothelioma origin.
- CK7-positive, CK20-positive: Suggests urothelial (bladder), pancreatobiliary, mucinous ovarian, or upper GI origin.
- CK7-negative, CK20-positive: Strongly suggests colorectal cancer or Merkel cell carcinoma.
- CK7-negative, CK20-negative: Raises the possibility of prostate cancer, hepatocellular carcinoma, clear cell renal carcinoma, germ cell tumors, squamous cell carcinoma, or neuroendocrine tumors.
This four-quadrant framework has been a workhorse in surgical pathology for decades.2PubMed Central. Revisiting the use of CK7 and CK20 immunohistochemical stains in pathological diagnoses It does not give a definitive answer on its own, but it dramatically shrinks the number of possibilities that need further investigation.
Telling Lung Cancer From Colorectal Cancer
One of the most common real-world uses of CK7/CK20 staining is separating lung adenocarcinoma from colorectal adenocarcinoma, especially when a tumor is found in the lung and the question is whether it started there or migrated from the colon. In one study, the CK7-positive/CK20-negative pattern correctly identified 96% of primary lung adenocarcinomas and 95% of metastatic lung adenocarcinomas. Meanwhile, all primary colorectal adenocarcinomas and 88% of metastatic colorectal adenocarcinomas showed the opposite pattern: CK7-negative/CK20-positive. Overall, the staining pattern correctly distinguished between the two cancers in 95% of cases.3PubMed Central. Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma
A separate study looked at cases where colorectal cancer had already metastasized to the lung and confirmed the pattern: about 91% of primary lung acinar adenocarcinomas stained positive for CK7, while only about 5% of colorectal cancer metastases in the lung did so. None of the primary colorectal cancers were CK7-positive.4PubMed Central. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer The clinical stakes here are significant. A primary lung tumor and a colorectal metastasis in the lung require entirely different treatment strategies, so getting this distinction right matters enormously.
Sorting Out Ovarian Masses
Another area where CK7 earns its keep is gynecologic pathology, particularly when a mass appears on or near the ovary. The question is often whether it is a primary ovarian cancer or a colon cancer that has spread to the ovary. One study found that virtually all primary and metastatic ovarian carcinomas stained positive for CK7, while nearly all primary and metastatic colonic carcinomas stained negative for it. The researchers concluded that CK7 was the single most helpful marker for making this distinction.5PubMed. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma
Stomach cancers add a wrinkle. A large study of nearly 300 gastric carcinomas found that about 71% stained positive for CK7, while only 9% of colorectal carcinomas did. The CK7-positive/CK20-negative pattern was most common in gastric cancers (46%), whereas the CK7-negative/CK20-positive pattern dominated in colorectal cancers (68%).6PubMed. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary So when an ovarian mass turns out to be CK7-positive, the pathologist knows it is far more likely ovarian or gastric than colorectal in origin, but additional markers are often needed to distinguish between those two possibilities.
Cancers of Unknown Primary Origin
Perhaps the most daunting scenario in oncology is when cancer cells appear in a biopsy, but nobody can find the original tumor. These “cancers of unknown primary” (CUP) account for a meaningful fraction of cancer diagnoses, and treatment depends heavily on identifying where the cancer began. CK7 and CK20 staining is typically one of the first steps.
In a retrospective survey of CUP cases, the most common staining pattern was CK7-positive/CK20-negative, found in about 55% of cases. The second most common was CK7-negative/CK20-negative at roughly 19%, followed by CK7-positive/CK20-positive at 15% and CK7-negative/CK20-positive at about 11%.7PubMed. Carcinoma of Unknown Primary Origin: Application of Immunohistochemistry With Emphasis to Different Cytokeratin 7 and 20 Staining Patterns Using either CK7 or CK20 alone can lead to wrong conclusions, but combining them narrows things considerably. One analysis found that dual staining correctly pinpointed lung origin in about 86% of primary pulmonary adenocarcinomas and colonic origin in about 77% of primary colon carcinomas.8European Journal of Cancer Prevention. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer
Researchers have consistently emphasized that CK7/CK20 typing works best as part of an algorithmic, probabilistic approach rather than a one-off binary test. The staining pattern points to a shortlist of likely origins, and then more targeted markers refine the diagnosis further.9PubMed. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma
Kidney Tumors and Tricky Look-Alikes
CK7 plays a surprisingly useful role in kidney pathology, where certain tumor types can look strikingly similar under the microscope but carry very different prognoses. Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are the classic pair that confuses pathologists, because both arise from similar cell types and can appear nearly identical on standard staining. Oncocytomas are benign. Chromophobe carcinomas are not.
CK7 helps break the tie. In one study, about 86% of chromophobe tumors stained positive for CK7, while roughly 83% of oncocytomas were negative. The test showed good sensitivity and specificity for telling them apart.10Journal of Microscopy and Ultrastructure. Diagnostic utility of vimentin, CD117, cytokeratin-7 and caveolin-1 in differentiation between clear cell renal cell carcinoma, chromophobe renal cell carcinoma and oncocytoma Another study reported even higher numbers: 94% CK7-positivity in chromophobe tumors. When CK7 was combined with two other markers (CD117 and Claudin-7) in a “three 7” panel, the specificity climbed to a perfect 1.0, meaning the triple-positive combination essentially ruled out oncocytoma and other mimics.11PubMed Central. Combined Immunohistochemistry for the “Three 7” Markers (CK7, CD117, and Claudin-7) Is Useful in the Diagnosis of Chromophobe Renal Cell Carcinoma and for the Exclusion of Mimics Clear cell renal cell carcinoma, the most common kidney cancer, is generally CK7-negative, adding another useful contrast.
Mesothelioma Versus Lung Adenocarcinoma
When cancer appears in the pleural space (the membrane lining the chest cavity), one of the first questions is whether it is a mesothelioma or a lung adenocarcinoma that has invaded the pleural lining. The treatment and prognosis are different, and the two can look confusingly alike in fluid samples. In one study of malignant pleural effusions, CK7 was positive in 100% of adenocarcinoma patients and negative in 100% of mesothelioma patients, a strikingly clean separation.12PubMed Central. The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion
That said, CK7 is rarely the only marker used in this scenario. Broader antibody panels including markers like calretinin, CEA, and WT1 are recommended because no single stain is foolproof across all subtypes of mesothelioma and lung cancer.13PubMed. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma CK20 can add further information: a strongly CK20-positive tumor in the pleura suggests a metastasis, most likely from the colon, rather than mesothelioma or primary lung cancer.14Cancer. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas
When CK7 Shows Up Where It Should Not
CK7 is typically absent from healthy liver cells and colon tissue, so when it does appear in those contexts, it can signal something going wrong beyond cancer. In an animal model of alcohol-related liver disease, liver cells began expressing CK7 only in those subjects that went on to develop more severe scarring (fibrosis), and the CK7 staining appeared on average more than four years before the fibrosis worsened. In normal liver, CK7 staining is confined to bile duct cells. The study suggested that hepatocellular CK7 expression could serve as an early warning sign of progressive liver damage in the setting of chronic alcohol exposure.15Elsevier / Journal of Hepatology. Cytokeratin 7 staining of hepatocytes predicts progression to more severe fibrosis in alcohol-fed baboons
In colorectal cancer, CK7 expression is the anomaly rather than the rule. But when colorectal tumors do express CK7, the outlook appears worse. One study found that patients whose colorectal tumors stained positive for CK7 had a five-year survival rate of about 29%, compared to roughly 65% for patients whose tumors were CK7-negative. In a statistical model adjusting for other variables, CK7 positivity roughly doubled the risk of cancer-specific death.16PubMed Central. Cytokeratin 7 expression as a predictor of an unfavorable prognosis in colorectal carcinoma The relationship between CK7 and prognosis is not always one-directional, though. In cervical squamous cell carcinoma, *decreased* CK7 expression correlated with disease progression. Patients with CK7-negative early-stage cervical cancer had worse outcomes and were more likely to have residual tumor cells after treatment.17PubMed. Decreased cytokeratin 7 expression correlates with the progression of cervical squamous cell carcinoma and poor patient outcomes So CK7’s prognostic meaning depends heavily on the cancer type: an unwelcome guest in the colon, but a protective companion in the cervix.
Beyond Diagnosis and Into Biology
For most of its history, CK7 has been treated purely as a passive marker, a protein that happens to be present or absent and serves as a useful flag. But more recent research suggests that the gene encoding CK7, called KRT7, may play an active role in how cancers grow and spread. In ovarian cancer cells, overexpressing KRT7 increased cell proliferation and migration, while silencing the gene reduced both. The mechanism appears to involve a well-known pathway that drives epithelial-mesenchymal transition, the process by which stationary cells acquire the ability to move and invade surrounding tissue.18PubMed Central. KRT7 promotes epithelial‑mesenchymal transition in ovarian cancer via the TGF‑β/Smad2/3 signaling pathway
A similar story is emerging in thyroid cancer. One analysis of papillary thyroid carcinoma identified KRT7 as a consistently overexpressed gene across multiple cell types within the tumor, and experimental work suggested it may promote metastasis through inflammatory signaling pathways.19Computational and Structural Biotechnology Journal. Consistent analysis of differentially expressed genes across 7 cell types in papillary thyroid carcinoma The implication is tantalizing: if KRT7 actively helps tumors spread, suppressing it might slow the cancer down. Early work has indicated that knocking out KRT7 can cause rapid tumor regression in experimental models, raising the possibility of therapeutic targeting.20PubMed Central. Emerging insights into keratin 7 roles in tumor progression and metastasis of cancers This is still preclinical territory, but it represents a shift in thinking about CK7 from inert diagnostic label to potential functional player.
Where CK7 Staining Falls Short
For all its usefulness, CK7/CK20 typing has clear limits. The four-quadrant system works on probabilities, not certainties, and some cancers simply do not follow the expected pattern. A subset of gastric cancers are CK7-negative. Occasional colorectal tumors are CK7-positive. Upper GI cancers can fall into almost any of the four quadrants. The system is most reliable when the result cleanly matches a strong pattern (like CK7-positive/CK20-negative for lung) and least reliable when the result is ambiguous or falls into a category shared by many different tumor types.
Machine-learning approaches are now being explored to improve on human-designed algorithms. One study tested a decision-tree model that incorporated CK7/CK20 staining along with other immunohistochemical and clinical data. The model achieved an accuracy of about 84%, which rose to nearly 86% when clinical information was added. Interestingly, the algorithm found that two other markers, CDX2 and TTF-1, actually outperformed CK7 and CK20 in predictive power and occupied the root of the decision tree, meaning they were the first and most informative splits the model used.21Wiley Online Library / Cancer Cytopathology. The role of cytokeratin 7/20 coordination revisited-Machine learning identifies improved interpretative algorithms for cell block immunohistochemistry in aspirates of metastatic carcinoma This does not mean CK7 and CK20 are being replaced; they still contribute to the model and remain widely available, inexpensive, and well-validated. But it does suggest that the next generation of diagnostic algorithms will treat them as part of a broader toolkit rather than the default starting point.
Even the earliest efforts to develop CK7-based antibodies for clinical use recognized that no single marker would be sufficient. The original monoclonal antibodies to keratin 7 were tested across a range of human tissues and cancers, and the researchers explicitly framed the work as building a panel-based approach to differential diagnosis.22PubMed Central. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas Decades later, the principle holds: CK7 is immensely useful, but it does its best work in conversation with other markers, clinical context, and increasingly, computational models that can weigh multiple variables at once.